Capstone Therapeutics (NASDAQ:CAPS) Trading 12.5% Higher – Here’s What Happened

Capstone Therapeutics Corp. (NASDAQ:CAPS)’s share price shot up 12.5% during trading on Friday . The company traded as high as $1.0750 and last traded at $1.06. 942,821 shares were traded during trading, a decline of 19% from the average session volume of 1,160,399 shares. The stock had previously closed at $0.9424.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Capstone Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Capstone Therapeutics currently has an average rating of “Sell”.

Capstone Therapeutics Stock Up 12.5%

The business’s fifty day simple moving average is $1.18 and its two-hundred day simple moving average is $1.49. The company has a market cap of $7.73 million, a PE ratio of -1.77 and a beta of -0.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.97 and a quick ratio of 0.41.

Capstone Therapeutics (NASDAQ:CAPS) last posted its earnings results on Friday, August 15th. The company reported ($0.13) earnings per share (EPS) for the quarter. The firm had revenue of $12.85 million for the quarter.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors bought a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned 0.40% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is currently owned by hedge funds and other institutional investors.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.